General Cancer News
Top Stories
Primary Colonic Lymphoma
POSTED: April 15, 2008The gastrointestinal tract is the most frequent site of extranodal lymphoma, representing approximately 6 to 12 per cent of all extranodal lymphomas.1,2 The stomach is the most frequently involved site followed by the small bowel and large bowel, where lymphomas represent 0.2 to 0.4 per cent of all colorectal tumors.3 It is a rare disease. Most of t...
Veltuzumab Enhances Radioimmunotherapy With Epratuzumab In Lymphoma Model
POSTED: April 15, 2008SAN DIEGO -- Immunomedics, Inc., a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today reported that combining veltuzumab, the Company's proprietary humanized anti-CD20 antibody, with yttrium-90-labeled epratuzumab, its humanized anti-CD22 antibody, improves treatment responses ...
Immunomedics' Pretargeting Method May Improve Radioimmunotherapy Of Cancer
POSTED: April 15, 2008SAN DIEGO -- Immunomedics, Inc, a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today announced that results presented at the 2008 Annual Meeting of AACR in San Diego, CA, demonstrated that pretargeting radioimmunotherapy (RAIT) with a trivalent bispecific monoclonal antibody (b...
Research Supports Role Of Inflammation To Determine Lung Cancer Risk, Particularly In African-American Women
POSTED: April 15, 2008SAN DIEGO -- Researchers at the Barbara Ann Karmanos Cancer Institute in Detroit today presented findings that support the role of inflammation in determining lung cancer risk, particularly among African-American women. The abstract titled, Cytokine SNPs Differentially Predict Risk of Non Small Cell Lung Cancer in African American and Caucasian...
Company's Patented Anti-Cancer Compounds Successfully Kill Difficult-To-Treat Colon, Brain And Lung Human Cancer Cells
POSTED: April 15, 2008PRINCETON, N.J. -- PhytoMedical Technologies, Inc., today announced that a series of positive outcomes from the Company's ongoing development of its patented anti-cancer compounds have prompted researchers to now undertake their first-ever efficacy studies, an important advancement in the drug development process. In contrast to other anti-ca...
Mouth Test Could Predict Lung Cancer Caused By Smoking
POSTED: April 15, 2008WASHINGTON -- Cells lining the mouth reflect the molecular damage that smoking does to the lining of the lungs, researchers at The University of Texas Anderson Cancer Center report on Sunday at the annual meeting of the American Association for Cancer Research. Examining oral tissue lining the mouth to gauge cancer-inducing molecular alterati...
Childhood Leukemia Survivors Struggle With Long-term Comorbidities
POSTED: April 15, 2008Survival rates of childhood cancers, especially leukemia, have improved greatly in the past three decades, but survivors of this disease still seem to face many health and lifestyle challenges as young adults. Depending on the extent of their disease and treatment methods, many continue to struggle with one or more life-long medical conditions and decre...
Stem Cells Created From Normal Skin Cells
POSTED: April 15, 2008STANFORD, Calif. -- U.S. scientists say they have developed a technique that turns normal skin cells into rare cancer stem cells. The Stanford University Medical Center researchers said cancer stem cells are thought to be the ones that drive a cancer, and are therefore the targets of any cancer therapy that must kill them in order to be effec...
Cynthia Nixon To Serve As Ambassador For Susan G. Komen For The Cure
POSTED: April 15, 2008DALLAS -- Award-winning actress, Cynthia Nixon, best known for her role as Miranda on the long-running television series Sex and the City, joins Susan G. Komen for the Cure, the world's largest breast cancer advocacy organization, as an Ambassador. Nixon will share her personal experience with breast cancer, attend key events and reach millions ...
Data Shows Non-invasive Assay Effectively Identifies Melanoma
POSTED: April 15, 2008LA JOLLA, Calif. -- DermTech, a biotechnology company developing molecular diagnostics for the early detection of melanoma and other diseases, will present data at the American Association of Cancer Research on its non-invasive assay that distinguishes melanoma from benign moles. The study entitled: "A Non-invasive Genomic Assay for the Detect...
